Anticalins^®: the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies

References

• Walsh G. Biopharmaceutical benchmarks 2006. Nat. Biotechnol.24(7), 769–776 (2006).
   PubMed Web of Science ®Google Scholar
• Carter PJ. Potent antibody therapeutics by design. Nat. Rev. Immunol.6(5), 343–357 (2006).
   PubMed Web of Science ®Google Scholar
• Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science305(5681), 200–205 (2004).
   PubMed Web of Science ®Google Scholar
• Steinman L. Immune therapy for autoimmune diseases. Science305(5681), 212–216 (2004).
   PubMed Web of Science ®Google Scholar
• Carter P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer1(2), 118–129 (2001).
   PubMed Web of Science ®Google Scholar
• Werner RG. Economic aspects of commercial manufacture of biopharmaceuticals. J. Biotechnol.113(1–3), 171–182 (2004).
   PubMed Web of Science ®Google Scholar
• Fiedler M, Skerra A. Non-antibody scaffolds. In: Handbook of Therapeutic Antibodies. Dübel S (Ed.). WILEY-VCH, Weinheim, Germany 467–499 (2007).
   Google Scholar
• Skerra A. Imitating the humoral immune response. Curr. Opin. Chem. Biol.7(6), 683–693 (2003).
   PubMed Web of Science ®Google Scholar
• Nygren PA, Skerra A. Binding proteins from alternative scaffolds. J. Immunol. Methods290(1–2), 3–28 (2004).
   PubMed Web of Science ®Google Scholar
• Binz HK, Amstutz P, Plückthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat. Biotechnol.23(10), 1257–1268 (2005).
   PubMed Web of Science ®Google Scholar
• Gill DS, Damle NK. Biopharmaceutical drug discovery using novel protein scaffolds. Curr. Opin. Biotechnol.17(6), 653–658 (2006).
   PubMed Web of Science ®Google Scholar
• Åkerström B, Borregaard N, Flower DR, Salier J-S, Lipocalins. Landes Bioscience, Georgetown, TX, USA (2006).
   Google Scholar
• Flower DR. The lipocalin protein family: structure and function. Biochem. J.3181–14 (1996).
   PubMed Web of Science ®Google Scholar
• Skerra A. Lipocalins as a scaffold. Biochim. Biophys. Acta1482(1–2), 337–350 (2000).
   PubMedGoogle Scholar
• Breustedt DA, Schönfeld DL, Skerra A. Comparative ligand-binding analysis of ten human lipocalins. Biochim. Biophys. Acta1764(2), 161–173 (2006).
   PubMedGoogle Scholar
• Lögdberg L, Wester L. Immunocalins: a lipocalin subfamily that modulates immune and inflammatory responses. Biochim. Biophys. Acta1482(1–2), 284–297 (2000).
   PubMedGoogle Scholar
• Schlehuber S, Skerra A. Lipocalins in drug discovery: from natural ligand-binding proteins to “anticalins”. Drug Discov. Today10(1), 23–33 (2005).
   PubMed Web of Science ®Google Scholar
• Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov.2(3), 214–221 (2003).
   PubMed Web of Science ®Google Scholar
• Nasreen A, Vogt M, Kim HJ, Eichinger A, Skerra A. Solubility engineering and crystallization of human apolipoprotein D. Protein Sci.15(1), 190–199 (2006).
   PubMedGoogle Scholar
• Kawaguchi R, Yu J, Honda J et al. A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A. Science315(5813), 820–825 (2007).
   PubMed Web of Science ®Google Scholar
• Hvidberg V, Jacobsen C, Strong RK, Cowland JB, Moestrup SK, Borregaard N. The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett.579(3), 773–777 (2005).
   PubMed Web of Science ®Google Scholar
• Wojnar P, Lechner M, Merschak P, Redl B. Molecular cloning of a novel lipocalin-1 interacting human cell membrane receptor using phage display. J. Biol. Chem.276(23), 20206–20212 (2001).
   PubMed Web of Science ®Google Scholar
• Fournier T, Medjoubi NN, Porquet D. α-1-acid glycoprotein. Biochim. Biophys. Acta1482(1–2), 157–171 (2000).
   PubMed Web of Science ®Google Scholar
• Paesen GC, Adams PL, Harlos K, Nuttall PA, Stuart DI. Tick histamine-binding proteins: isolation, cloning, and three-dimensional structure. Mol. Cell3(5), 661–671 (1999).
   PubMed Web of Science ®Google Scholar
• Couillin I, Maillet I, Vargaftig BB et al. Arthropod-derived histamine-binding protein prevents murine allergic asthma. J. Immunol.173(5), 3281–3286 (2004).
   PubMed Web of Science ®Google Scholar
• Waxman L, Connolly TM. Isolation of an inhibitor selective for collagen-stimulated platelet aggregation from the soft tick Ornithodoros moubata. J. Biol. Chem.268(8), 5445–5449 (1993).
   PubMed Web of Science ®Google Scholar
• Nunn MA, Sharma A, Paesen GC et al. Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata. J. Immunol.174(4), 2084–2091 (2005).
   PubMed Web of Science ®Google Scholar
• Francischetti IM, Ribeiro JM, Champagne D, Andersen J. Purification, cloning, expression, and mechanism of action of a novel platelet aggregation inhibitor from the salivary gland of the blood-sucking bug, Rhodnius prolixus. J. Biol. Chem.275(17), 12639–12650 (2000).
   PubMedGoogle Scholar
• Montfort WR, Weichsel A, Andersen JF. Nitrophorins and related antihemostatic lipocalins from Rhodnius prolixus and other blood-sucking arthropods. Biochim. Biophys. Acta1482(1–2), 110–118 (2000).
   PubMed Web of Science ®Google Scholar
• Andersen JF, Francischetti IM, Valenzuela JG, Schuck P, Ribeiro JM. Inhibition of hemostasis by a high affinity biogenic amine-binding protein from the saliva of a blood-feeding insect. J. Biol. Chem.278(7), 4611–4617 (2003).
   PubMed Web of Science ®Google Scholar
• Noeske-Jungblut C, Kratzschmar J, Haendler B et al. An inhibitor of collagen-induced platelet aggregation from the saliva of Triatoma pallidipennis. J. Biol. Chem.269(7), 5050–5053 (1994).
   PubMed Web of Science ®Google Scholar
• Fuentes-Prior P, Noeske-Jungblut C, Donner P, Schleuning WD, Huber R, Bode W. Structure of the thrombin complex with triabin, a lipocalin-like exosite-binding inhibitor derived from a triatomine bug. Proc. Natl Acad. Sci. USA94(22), 11845–11850 (1997).
   PubMed Web of Science ®Google Scholar
• Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol. Cell.10(5), 1033–1043 (2002).
   PubMed Web of Science ®Google Scholar
• Holmes MA, Paulsene W, Jide X, Ratledge C, Strong RK. Siderocalin (Lcn 2) also binds carboxymycobactins, potentially defending against mycobacterial infections through iron sequestration. Structure13(1), 29–41 (2005).
   PubMed Web of Science ®Google Scholar
• Flo TH, Smith KD, Sato S et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature432(7019), 917–921 (2004).
   PubMed Web of Science ®Google Scholar
• Yang J, Goetz D, Li JY et al. An iron delivery pathway mediated by a lipocalin. Mol. Cell10(5), 1045–1056 (2002).
   PubMed Web of Science ®Google Scholar
• Mori K, Lee HT, Rapoport D et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J. Clin. Invest.115(3), 610–621 (2005).
   PubMed Web of Science ®Google Scholar
• Schmidt-Ott KM, Mori K, Kalandadze A et al. Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney epithelia. Curr. Opin. Nephrol. Hypertens.15(4), 442–449 (2006).
   PubMed Web of Science ®Google Scholar
• Breustedt DA, Korndörfer IP, Redl B, Skerra A. The 1.8-Å crystal structure of human tear lipocalin reveals an extended branched cavity with capacity for multiple ligands. J. Biol. Chem.280(1), 484–493 (2005).
   PubMedGoogle Scholar
• Fluckinger M, Haas H, Merschak P, Glasgow BJ, Redl B. Human tear lipocalin exhibits antimicrobial activity by scavenging microbial siderophores. Antimicrob. Agents Chemother.48(9), 3367–3372 (2004).
   PubMed Web of Science ®Google Scholar
• Schmidt FS, Skerra A. The bilin-binding protein of Pieris brassicae. cDNA sequence and regulation of expression reveal distinct features of this insect pigment protein. Eur. J. Biochem.219(3), 855–863 (1994).
   PubMedGoogle Scholar
• Beste G, Schmidt FS, Stibora T, Skerra A. Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proc. Natl Acad. Sci. USA96(5), 1898–1903 (1999).
   PubMed Web of Science ®Google Scholar
• Skerra A. ‘Anticalins’: a new class of engineered ligand-binding proteins with antibody-like properties. J. Biotechnol.74(4), 257–275 (2001).
   PubMedGoogle Scholar
• Voss EWJ. Fluorescein Hapten: An Immunological Probe. CRC Press, FL, USA (1984).
   Google Scholar
• Vopel S, Mühlbach H, Skerra A. Rational engineering of a fluorescein-binding anticalin for improved ligand affinity. Biol. Chem.386(11), 1097–1104 (2005).
   PubMedGoogle Scholar
• McCreery T. Digoxigenin labeling. Mol. Biotechnol.7(2), 121–124 (1997).
   PubMed Web of Science ®Google Scholar
• Hauptman PJ, Kelly RA. Digitalis. Circulation99(9), 1265–1270 (1999).
   PubMed Web of Science ®Google Scholar
• Schlehuber S, Beste G, Skerra A. A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin. J. Mol. Biol.297(5), 1105–1120 (2000).
   PubMed Web of Science ®Google Scholar
• Korndörfer IP, Beste G, Skerra A. Crystallographic analysis of an “anticalin” with tailored specificity for fluorescein reveals high structural plasticity of the lipocalin loop region. Proteins Struct. Funct. Genet.53(1), 121–129 (2003).
   PubMed Web of Science ®Google Scholar
• Korndörfer IP, Schlehuber S, Skerra A. Structural mechanism of specific ligand recognition by a lipocalin tailored for the complexation of digoxigenin. J. Mol. Biol.330(2), 385–396 (2003).
   PubMed Web of Science ®Google Scholar
• Lechat P, Mudgett-Hunter M, Margolies MN, Haber E, Smith TW. Reversal of lethal digoxin toxicity in guinea pigs using monoclonal antibodies and Fab fragments. J. Pharmacol. Exp. Ther.229(1), 210–213 (1984).
   PubMed Web of Science ®Google Scholar
• Kelly R, Peim A, Walz A et al. Reversal of digoxin cardiac toxicity by an Anticalin (Digical II) in the anaesthetized guinea pig. J. Physiol.560P, PC7 (2004).
   Google Scholar
• Vogt M, Skerra A. Construction of an artificial receptor protein (“anticalin”) based on the human apolipoprotein D. Chem. Bio. Chem.5(2), 191–199 (2004).
   Google Scholar
• Allison JP. Blockade of T cell inhibitory signals: a new paradigm in tumor immunotherapy? Cancer Immun.5(Suppl. 1), 9 (2005).
   PubMedGoogle Scholar
• Keler T, Halk E, Vitale L et al. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J. Immunol.171(11), 6251–6259 (2003).
   PubMed Web of Science ®Google Scholar
• Camacho LH, Ribas A, Glaspy JA et al. Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies. J. Clin. Oncol. (Meeting Abstracts)22(14 Suppl.), 2505 (2004).
   PubMedGoogle Scholar
• Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA100(14), 8372–8377 (2003).
   PubMed Web of Science ®Google Scholar
• Muhsin M, Graham J, Kirkpatrick P. Bevacizumab. Nat. Rev. Drug Discov.3(12), 995–996 (2004).
   PubMed Web of Science ®Google Scholar
• Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat. Rev. Drug Discov.5(2), 147–159 (2006).
   PubMed Web of Science ®Google Scholar
• Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol.23(9), 1137–1146 (2005).
   PubMed Web of Science ®Google Scholar
• Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat. Rev. Cancer2(9), 683–693 (2002).
   PubMed Web of Science ®Google Scholar
• Pastan I. Immunotoxins containing Pseudomonas exotoxin A: a short history. Cancer Immunol. Immunother.52(5), 338–341 (2003).
   PubMed Web of Science ®Google Scholar
• Palmisano GL, Tazzari PL, Cozzi E et al. Expression of CTLA-4 in nonhuman primate lymphocytes and its use as a potential target for specific immunotoxin-mediated apoptosis: results of in vitro studies. Clin. Exp. Immunol.135(2), 259–266 (2004).
   PubMedGoogle Scholar
• Schlehuber S, Skerra A. Duocalins: engineered ligand-binding proteins with dual specificity derived from the lipocalin fold. Biol. Chem.382(9), 1335–1342 (2001).
   PubMed Web of Science ®Google Scholar
• Kenanova V, Wu AM. Tailoring antibodies for radionuclide delivery. Expert Opin. Drug Deliv.3(1), 53–70 (2006).
   PubMedGoogle Scholar
• Reichert J, Pavlou A. Monoclonal antibodies market. Nat. Rev. Drug Discov.3(5), 383–384 (2004).
   PubMed Web of Science ®Google Scholar
• Axelsson L, Bergenfeldt M, Ohlsson K. Studies of the release and turnover of a human neutrophil lipocalin. Scand. J. Clin. Lab. Invest.55(7), 577–588 (1995).
   PubMed Web of Science ®Google Scholar
• Osborn BL, Olsen HS, Nardelli B et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin–interferon-α fusion protein in cynomolgus monkeys. J. Pharmacol. Exp. Ther.303(2), 540–548 (2002).
   PubMed Web of Science ®Google Scholar
• Dennis MS, Zhang M, Meng YG et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem.277(38), 35035–35043 (2002).
   PubMed Web of Science ®Google Scholar
• Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res.21(6), 897–903 (2004).
   PubMed Web of Science ®Google Scholar
• Van Walle I, Gansemans Y, Parren P, Stas P, Lasters L. Immunogenicity screening in protein drug development. Expert Opin. Biol. Ther.7, 405–418 (2007).
   PubMed Web of Science ®Google Scholar
• Lundegaard C, Nielsen M, Lund O. The validity of predicted T-cell epitopes. Trends Biotechnol.24(12), 537–538 (2006).
   PubMed Web of Science ®Google Scholar